Loading clinical trials...
Loading clinical trials...
Efficacy of COVID 19 SARS-CoV-2 mRNA Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication (SARSmRNA_MS)
Conditions
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Locations
1
United States
Providence Neurological Specialties West
Portland, Oregon, United States
Start Date
July 11, 2022
Primary Completion Date
October 4, 2022
Completion Date
October 25, 2022
Last Updated
April 3, 2023
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07376772
NCT07426991
Lead Sponsor
Providence Health & Services
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions